Pharmaceutical intermediates
Nafamostat mesylate Intermediates
3 pharmaceutical intermediates for Nafamostat mesylate. Indication: Pancreatitis; Disseminated Intravascular Coagulation.
About Nafamostat mesylate
- Indication
- Pancreatitis; Disseminated Intravascular Coagulation
- Approved Date
- 10/01/1986
Available intermediates
3 intermediates currently listed for Nafamostat mesylate. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 6-Cyano-2-naphthol | 52927-22-7 | / | / |
| 6-Amidino-2-naphtol methanesulfonate | 82957-06-0 | / | / |
| 4-Guanidinobenzoic acid hydrochloride | 42823-46-1 | / | / |
Building toward Nafamostat mesylate?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →